Nexien Biopharma Inc - Understand $nxen stock

$NXEN Market Cap: $920 Thousand

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$152.6K

TTM

Current Assets

$4.183K

Q2 2024

Current Liabilities

$365.4K

Q2 2024

Current Ratio

1.14%

Q2 2024

Total Assets

$4.183K

Q2 2024

Total Liabilities

$365.4K

Q2 2024

Book Value

-$361.2K

Q2 2024

Cash

$4.183K

Q2 2024

P/E

-6.029

Nov 14, 2024 EST

Free Cash Flow

Revenues

Revenue YoY Change

Revenues

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue				$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$149.6M	$162.0M	$184.4M	$192.8M	$197.3M	$229.4M	$265.9M	$259.1M	$254.7M	$238.2M	$170.2M	$133.0M	$98.40M	$75.00M	$62.00M
YoY Change												-7.65%	-12.15%	-4.36%	-2.28%	-13.99%	-13.73%	2.62%	1.73%	6.93%	39.95%	27.97%	35.16%	31.2%	20.97%	17.2%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2021	2020	2019	2018	2017	2016	2015	2014	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$149.6M	$162.0M	$184.4M	$192.8M	$197.3M	$229.4M	$265.9M	$259.1M	$254.7M	$238.2M	$170.2M	$133.0M	$98.40M	$75.00M	$62.00M
Cost Of Revenue									$124.8M	$137.2M	$147.0M	$151.9M	$160.4M	$205.9M	$211.6M	$207.2M	$204.9M	$170.5M	$123.1M	$93.70M	$69.00M	$52.60M	$45.10M
Gross Profit									$24.80M	$24.70M	$37.30M	$40.90M	$36.90M	$23.50M	$54.30M	$51.90M	$49.80M	$67.70M	$47.20M	$39.40M	$29.40M	$22.50M	$16.90M
Gross Profit Margin									16.58%	15.25%	20.23%	21.21%	18.7%	10.24%	20.42%	20.03%	19.55%	28.42%	27.73%	29.62%	29.88%	30.0%	27.26%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Selling, General & Admin		$300.0K	$564.0K	$1.844M	$2.546M	$3.869M	$1.166M	$15.83K	$16.35K	$46.68K	$0.00	$36.30M	$38.30M	$37.40M	$40.00M	$40.10M	$47.00M	$52.40M	$55.40M	$65.10M	$58.00M	$41.90M	$33.40M	$23.60M	$18.30M	$16.00M
YoY Change		-46.81%	-69.41%	-27.58%	-34.2%	231.71%	7268.35%	-3.18%	-64.97%			-5.22%	2.41%	-6.5%	-0.25%	-14.68%	-10.31%	-5.42%	-14.9%	12.24%	38.42%	25.45%	41.53%	28.96%	14.38%	17.65%
% of Gross Profit												146.37%	155.06%	100.27%	97.8%	108.67%	200.0%	96.5%	106.74%	130.72%	85.67%	88.77%	84.77%	80.27%	81.33%	94.67%
Research & Development	$0.00	$0.00	$0.00	$0.00	$0.00	$63.86K	$116.8K
YoY Change					-100.0%	-45.32%
% of Gross Profit
Depreciation & Amortization												$4.440M	$4.780M	$5.490M	$6.240M	$6.340M	$8.310M	$9.480M	$9.580M	$8.260M	$6.020M	$4.210M	$2.920M	$1.930M	$1.360M
YoY Change												-7.11%	-12.93%	-12.02%	-1.58%	-23.71%	-12.34%	-1.04%	15.98%	37.21%	42.99%	44.18%	51.3%	41.91%
% of Gross Profit												17.9%	19.35%	14.72%	15.26%	17.18%	35.36%	17.46%	18.46%	16.59%	8.89%	8.92%	7.41%	6.56%	6.04%
Operating Expenses	$155.7K	$282.6K	$564.0K	$1.844M	$2.637M	$3.933M	$1.283M	$15.83K	$16.35K	$46.68K	$0.00	$31.80M	$33.50M	$32.70M	$35.50M	$35.10M	$40.30M	$44.50M	$47.20M	$59.40M	$53.50M	$38.40M	$30.30M	$21.00M	$16.40M	$14.40M
YoY Change	-44.92%	-49.89%	-69.41%	-30.07%	-32.96%	206.5%	8006.13%	-3.18%	-64.97%			-5.07%	2.45%	-7.89%	1.14%	-12.9%	-9.44%	-5.72%	-20.54%	11.03%	39.32%	26.73%	44.29%	28.05%	13.89%	15.2%
Operating Profit												-$7.000M	-$8.800M	$4.600M	$5.400M	$1.800M	-$16.80M	$9.800M	$4.700M	-$9.600M	$14.20M	$8.800M	$9.100M	$8.400M	$6.100M	$2.500M
YoY Change												-20.45%	-291.3%	-14.81%	200.0%	-110.71%	-271.43%	108.51%	-148.96%	-167.61%	61.36%	-3.3%	8.33%	37.7%	144.0%	4.17%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2024	2023	2022	2021	2020	2017	2016	2015	2014	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Interest Expense		-$100.0K	-$62.37K	-$16.18K	-$30.00	-$5.840K	-$4.640K	-$1.770K	$0.00	-$4.800M	-$2.300M	-$2.300M	-$2.300M	-$100.0K	-$1.800M	-$2.900M	-$5.100M	-$4.000M	-$2.800M	-$2.100M	-$500.0K	-$600.0K	-$900.0K	-$900.0K
YoY Change		60.33%	285.48%	53833.33%		25.86%	162.15%			108.7%	0.0%	0.0%	2200.0%	-94.44%	-37.93%	-43.14%	27.5%	42.86%	33.33%	320.0%	-16.67%	-33.33%	0.0%	125.0%
% of Operating Profit												-50.0%	-42.59%	-5.56%		-29.59%	-108.51%		-19.72%	-23.86%	-5.49%	-7.14%	-14.75%	-36.0%
Other Income/Expense, Net	-$83.45K	-$79.29K	-$62.37K	-$16.18K						$0.00	$0.00	$0.00	-$300.0K	-$1.800M	-$800.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	5.24%	27.15%	285.56%									-100.0%	-83.33%	125.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Pretax Income		-$400.0K	-$626.4K	-$1.860M	-$2.672M	-$4.301M	-$1.283M	-$21.67K	-$20.99K	-$48.44K	$0.00	-$12.60M	-$10.40M	$2.300M	$3.700M	$1.000M	-$48.70M	$7.300M	$600.0K	-$20.10M	$11.30M	$6.600M	$8.500M	$7.800M	$5.200M	$1.600M
YoY Change		-36.14%	-66.32%	-30.38%	-37.88%	235.17%	5821.55%	3.24%	-56.67%			21.15%	-552.17%	-37.84%	270.0%	-102.05%	-767.12%	1116.67%	-102.99%	-277.88%	71.21%	-22.35%	8.97%	50.0%	225.0%	-20.0%
Income Tax												$0.00	-$600.0K	$0.00	$0.00	$0.00	-$4.500M	$2.400M	$200.0K	-$7.300M	$4.300M	$2.400M	$3.500M	$3.300M	$2.100M	$600.0K
% Of Pretax Income														0.0%	0.0%	0.0%		32.88%	33.33%		38.05%	36.36%	41.18%	42.31%	40.38%	37.5%
Net Earnings	-$239.1K	-$361.9K	-$626.4K	-$1.860M	-$2.672M	-$4.301M	-$1.283M	-$21.67K	-$20.99K	-$48.44K	$0.00	-$12.80M	-$9.800M	$2.300M	$3.700M	$2.600M	-$43.10M	$4.900M	$400.0K	-$12.80M	$7.000M	$4.200M	$6.200M	$4.500M	$3.100M	$900.0K
YoY Change	-33.93%	-42.22%	-66.32%	-30.38%	-37.88%	235.17%	5821.55%	3.24%	-56.67%			30.61%	-526.09%	-37.84%	42.31%	-106.03%	-979.59%	1125.0%	-103.13%	-282.86%	66.67%	-32.26%	37.78%	45.16%	244.44%	-35.71%
Net Earnings / Revenue												-8.56%	-6.05%	1.25%	1.92%	1.32%	-18.79%	1.84%	0.15%	-5.03%	2.94%	2.47%	4.66%	4.57%	4.13%	1.45%
Basic Earnings Per Share	$0.00	-$0.01	-$0.01	-$0.03
Diluted Earnings Per Share	$0.00	-$0.01	-$10.83K	-$33.57K	-$49.55K	-$84.28K	-$30.07K	-$5.725K	-$5.545K	-$12.80K	$0.00	-$32.00M	-$24.50M	$5.750M	$9.250M	$26.00M	-$431.0M	$24.50M	$4.000M	-$128.0M	$70.00M	$42.00M	$62.00M	$45.00M	$31.00M	$9.000M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Cash & Short-Term Investments	$0.00	$116.9K	$18.04K	$10.79K	$146.4K	$819.7K	$0.00	$0.00	$0.00	$0.00	$1.300M	$1.300M	$4.300M	$1.500M	$26.50M	$42.90M	$1.700M	$1.300M	$2.400M	$3.700M	$1.400M	$1.200M	$5.900M	$1.500M	$300.0K
YoY Change	-100.0%	548.0%	67.19%	-92.63%	-82.15%						0.0%	-69.77%	186.67%	-94.34%	-38.23%	2423.53%	30.77%	-45.83%	-35.14%	164.29%	16.67%	-79.66%	293.33%	400.0%
Cash & Equivalents											$1.300M	$1.300M	$4.300M	$1.500M	$26.50M	$42.90M	$1.700M	$1.300M	$2.400M	$3.700M	$1.400M	$1.200M	$5.900M	$1.500M	$300.0K
Short-Term Investments
Other Short-Term Assets	$0.00	$7.620K	$7.500K	$12.00K	$164.3K	$15.00K					$8.100M	$8.200M	$3.200M	$2.900M	$3.300M	$7.000M	$4.200M	$4.300M	$5.300M	$5.100M	$2.600M	$1.400M	$500.0K	$200.0K	$100.0K
YoY Change	-100.0%	1.6%	-37.5%	-92.7%	995.4%						-1.22%	156.25%	10.34%	-12.12%	-52.86%	66.67%	-2.33%	-18.87%	3.92%	96.15%	85.71%	180.0%	150.0%	100.0%
Inventory											$27.80M	$22.50M	$22.40M	$24.00M	$22.50M	$23.10M	$34.30M	$30.90M	$35.10M	$39.60M	$26.20M	$21.90M	$11.90M	$8.800M	$7.700M
Prepaid Expenses
Receivables											$17.60M	$18.60M	$22.00M	$22.60M	$25.20M	$29.50M	$36.60M	$43.80M	$37.00M	$31.90M	$24.10M	$19.60M	$15.20M	$11.70M	$10.10M
Other Receivables											$0.00	$0.00	$0.00	$0.00	$0.00	$1.700M	$0.00	$0.00	$3.200M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$0.00	$124.5K	$25.54K	$22.79K	$310.7K	$834.7K	$0.00	$0.00	$0.00	$0.00	$54.80M	$50.60M	$51.90M	$50.90M	$77.60M	$104.1M	$76.80M	$80.40M	$83.00M	$80.20M	$54.40M	$44.00M	$33.40M	$22.20M	$18.20M
YoY Change	-100.0%	387.55%	12.07%	-92.66%	-62.78%						8.3%	-2.5%	1.96%	-34.41%	-25.46%	35.55%	-4.48%	-3.13%	3.49%	47.43%	23.64%	31.74%	50.45%	21.98%
Property, Plant & Equipment											$11.00M	$14.50M	$14.00M	$17.50M	$18.40M	$21.50M	$36.80M	$45.40M	$54.00M	$46.70M	$32.30M	$24.20M	$15.10M	$8.200M	$4.600M
YoY Change											-24.14%	3.57%	-20.0%	-4.89%	-14.42%	-41.58%	-18.94%	-15.93%	15.63%	44.58%	33.47%	60.26%	84.15%	78.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets						$0.00					$900.0K	$500.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$500.0K	$300.0K
YoY Change											80.0%												-100.0%	66.67%
Total Long-Term Assets	$0.00	$0.00	$0.00	$0.00	$0.00	$437.6K	$0.00	$0.00	$0.00	$0.00	$11.90M	$14.60M	$14.00M	$17.50M	$18.40M	$21.50M	$36.80M	$45.40M	$54.00M	$46.70M	$32.20M	$24.30M	$15.10M	$8.700M	$5.000M
YoY Change					-100.0%						-18.49%	4.29%	-20.0%	-4.89%	-14.42%	-41.58%	-18.94%	-15.93%	15.63%	45.03%	32.51%	60.93%	73.56%	74.0%
Total Assets	$0.00	$124.5K	$25.54K	$22.79K	$310.7K	$1.272M	$0.00	$0.00	$0.00	$0.00	$66.70M	$65.20M	$65.90M	$68.40M	$96.00M	$125.6M	$113.6M	$125.8M	$137.0M	$126.9M	$86.60M	$68.30M	$48.50M	$30.90M	$23.20M
YoY Change
Accounts Payable	$0.00	$20.40K	$6.380K	$17.15K	$44.75K	$88.79K	$60.00K	$50.00K	$40.00K	$0.00	$12.20M	$7.600M	$10.70M	$12.10M	$8.500M	$4.500M	$13.00M	$16.50M	$20.70M	$21.20M	$21.70M	$14.50M	$8.200M	$6.000M	$4.200M
YoY Change	-100.0%	219.75%	-62.8%	-61.68%	-49.6%	47.98%	20.0%	25.0%			60.53%	-28.97%	-11.57%	42.35%	88.89%	-65.38%	-21.21%	-20.29%	-2.36%	-2.3%	49.66%	76.83%	36.67%	42.86%
Accrued Expenses	$0.00	$45.00K	$20.00K				$12.24K	$6.390K	$1.760K	$0.00	$7.500M	$8.500M
YoY Change	-100.0%	125.0%					91.55%	263.07%			-11.76%
Deferred Revenue
YoY Change
Short-Term Debt	$200.0K	$176.7K	$12.94K	$12.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	13.17%	1265.77%	7.83%
Long-Term Debt Due												$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$2.200M	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change																			-100.0%
Total Short-Term Liabilities	$300.0K	$242.1K	$39.32K	$29.15K	$44.75K	$88.79K	$91.58K	$69.90K	$48.92K	$0.00	$19.70M	$16.10M	$22.60M	$27.30M	$23.80M	$18.30M	$32.00M	$35.20M	$37.80M	$38.80M	$33.20M	$23.50M	$13.10M	$13.00M	$8.400M
YoY Change	23.91%	515.77%	34.89%	-34.86%	-49.6%	-3.05%	31.02%	42.89%			22.36%	-28.76%	-17.22%	14.71%	30.05%	-42.81%	-9.09%	-6.88%	-2.58%	16.87%	41.28%	79.39%	0.77%	54.76%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$37.70M	$27.40M	$11.90M	$12.40M	$5.200M	$200.0K	$34.00M	$48.70M	$53.60M	$31.60M	$24.50M	$9.700M	$6.300M	$7.000M	$7.000M
YoY Change											37.59%	130.25%	-4.03%	138.46%	2500.0%	-99.41%	-30.18%	-9.14%	69.62%	28.98%	152.58%	53.97%	-10.0%	0.0%
Other Long-Term Liabilities												$0.00	$0.00	$0.00	$2.000M	$2.000M	$0.00	$0.00	$3.900M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change														-100.0%	0.0%			-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$37.70M	$27.40M	$11.90M	$12.40M	$7.200M	$2.200M	$34.00M	$48.70M	$57.50M	$31.60M	$24.50M	$9.700M	$6.300M	$7.000M	$7.000M
YoY Change											37.59%	130.25%	-4.03%	72.22%	227.27%	-93.53%	-30.18%	-15.3%	81.96%	28.98%	152.58%	53.97%	-10.0%	0.0%
Total Liabilities	$300.0K	$242.1K	$39.32K	$29.15K	$44.75K	$88.79K	$91.58K	$69.90K	$48.92K	$0.00	$57.30M	$43.50M	$34.60M	$39.60M	$90.80M	$123.0M	$67.90M	$85.80M	$97.40M	$74.50M	$61.40M	$36.60M	$23.10M	$20.40M	$15.80M
YoY Change	23.91%	515.77%	34.89%	-34.86%	-49.6%	-3.05%	31.02%	42.89%			31.72%	25.72%	-12.63%	-56.39%	-26.18%	81.15%	-20.86%	-11.91%	30.74%	21.34%	67.76%	58.44%	13.24%	29.11%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2024	2023	2022	2021
Basic Shares Outstanding	66.19M shares	62.33M shares	57.86M shares	55.40M shares
Diluted Shares Outstanding	66.19M shares	62.33M shares	57.86M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $920.04 Thousand

About Nexien Biopharma Inc

Nexien BioPharma, Inc. engages in the development and commercialization of Food and Drug Administration-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company is headquartered in Glendale, Colorado and currently employs 0 full-time employees. The company went IPO on 2001-07-11. The firm is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The firm's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Industry: Pharmaceutical Preparations Peers: CNBX Pharmaceuticals Inc Dermata Therapeutics Inc Johnson & Johnson Senestech Inc GRI Bio Inc